Search Results 1231-1240 of 17043 for monoclonal antibody

1. RBX2660 Administered by Colonoscopy for Recurrent Clostridioides difficile Infection - Mayo Clinic

   Receipt of CDI vaccine or treatment with CDI monoclonal antibodies: Within 12 months before screening; or; Between screening and baseline. Compromised immune ...

2. Safety and Efficacy of ALLO-715 and ALLO-647 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) - Mayo Clinic

   ... antibody (ALLO-647)-containing regimen in 43 patients with relapsed/refractory multiple myeloma as part A of the ongoing first-in-human phase 1 UNIVERSAL trial.

3. Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (FRAPPE) - Mayo Clinic

   ... monoclonal antibody - Treatment with IV anti-cancer therapy =< 3 weeks prior to registration or with oral anti-cancer therapy =< 1 week prior to ...

4. Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer - Mayo Clinic

   NOTE: if there is a history of prior malignancy, they must not be receiving other specific treatment (cytotoxics, monoclonal antibodies, small molecule ...

5. A Study to Evaluate the Combination of Binimetinib and Palbociclib in Treating Patients with KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer - Mayo Clinic

   Prior treatment ≤ 21 days prior to registration/randomization with any other chemotherapy, small molecule inhibitor (e.g., regorafenib), monoclonal antibody, ...

6. Primary Immunodeficiency Center in Minnesota - Overview - Mayo Clinic

   Some types of primary immunodeficiency cause a shortage of antibodies, the ... The combination of a history of infections, blood antibody and immune ...

7. Smallpox and mpox vaccine, live (injection route) - Side effects & uses - Mayo Clinic

   It works by causing your immune system to produce its own protection (antibodies) against the virus. This vaccine is to be given only by or under the ...

8. Metabolic Biotinylation - Virology, Vector and Vaccine Engineering: Michael A. Barry - Mayo Clinic Research

   Finally, structural compatibility problems are avoided between ligands and vector proteins such that large ligands (for example, antibodies) and nonprotein ...

9. A Study to Evaluate Tazemetostat and Pembrolizumab to Treat Advanced Urothelial Carcinoma - Mayo Clinic

   Patients who have had a prior monoclonal antibody within 4 weeks prior to study day 1 are not eligible. Patients with a known additional malignancy that is ...

10. Safety and Efficacy of B-cell Activating Factor Receptor (BAFFR)-based Chimeric Antigen Receptor T-cells in Subjects with Relapsed or Refractory BAFFR-expressing B-cell Hematologic Malignancies - Mayo Clinic

    For Follicular Lymphoma, patients must have received prior chemoimmunotherapy including an antibody directed against CD20. For Mantle Cell Lymphoma ...